Journal
MOLECULES
Volume 20, Issue 1, Pages 1176-1191Publisher
MDPI AG
DOI: 10.3390/molecules20011176
Keywords
drug discovery; compound screening; kinase assays; molecular modeling; molecular docking; ATP-competitive inhibitors; non-competitive inhibition; Neks
Funding
- Sao Paulo Research Foundation (FAPESP)
- ConselhoNacional de Pesquisa e Desenvolvimento (CNPq)
- Centro Nacional de PesquisaemEnergia e Materiais (CNPEM)
Ask authors/readers for more resources
Human Neks are a conserved protein kinase family related to cell cycle progression and cell division and are considered potential drug targets for the treatment of cancer and other pathologies. We screened the activation loop mutant kinases hNek1 and hNek2, wild-type hNek7, and five hNek6 variants in different activation/phosphorylation statesand compared them against 85 compounds using thermal shift denaturation. We identified three compounds with significant T-m shifts: JNK Inhibitor II for hNek1(Delta 262-1258)-(T162A), Isogranulatimide for hNek6(S206A), andGSK-3 Inhibitor XIII for hNek7wt. Each one of these compounds was also validated by reducing the kinases activity by at least 25%. The binding sites for these compounds were identified by in silico docking at the ATP-binding site of the respective hNeks. Potential inhibitors were first screened by thermal shift assays, had their efficiency tested by a kinase assay, and were finally analyzed by molecular docking. Our findings corroborate the idea of ATP-competitive inhibition for hNek1 and hNek6 and suggest a novel non-competitive inhibition for hNek7 in regard to GSK-3 Inhibitor XIII. Our results demonstrate that our approach is useful for finding promising general and specific hNekscandidate inhibitors, which may also function as scaffolds to design more potent and selective inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available